Castle Rock Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-2,983
Closed -$234K 247
2021
Q3
$234K Sell
2,983
-8,796
-75% -$738K 0.08% 233
2021
Q2
$997K Buy
11,779
+304
+3% +$25.8K 0.37% 93
2021
Q1
$1.01M Buy
11,475
+1,718
+18% +$170K 0.41% 86
2020
Q4
$1.08M Buy
+9,757
New +$777K 0.45% 70

Other funds holding ARKG

Castle Rock Wealth Management's ARKG Position: Q4 2021 in Review

Castle Rock Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 2,983 shares — an estimated $234K sold.

Castle Rock Wealth Management first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $1.08M in Q4 2020. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Castle Rock Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Castle Rock Wealth Management sold 2,983 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $234K.
  • Castle Rock Wealth Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
  • Castle Rock Wealth Management's ARK Genomic Revolution ETF position peaked at $1.08M in Q4 2020.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Castle Rock Wealth Management's 13F filing for Q4 2021, filed 2 Feb 2022.